Cuba-Rushford Junior/Senior High School has announced the honor rolls for the second quarter of the 2024–25 school year ...

Nemluvio, which was also approved for prurigo nodularis, becomes Galderma’s first approved biologic in its dermatology ...

Corporate borrowers shrugged off fears over inflation and concerns over tariffs to print tight trades and pay for ...

According to Statifacts, the global clinical trials market size is calculated at USD 126.30 billion in 2025 and is expected to reach around USD 186.09 billion by 2034, growing at a CAGR of 4.4% from ...

Eli Lilly and Company’s LLY shares have risen 4.3% since it reported fourth-quarter results on Feb. 6. Lilly’s fourth-quarter ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on UnitedHealth (UNH – Research Report) and Eli ...

"I'm not much of a crier," Hawks football coach Tony Woolfolk said. "But I was so proud and loved those guys so much that I ...

Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative.

Request To Download Free Sample of This Strategic Report @ Highlighted with 99 tables and 79 figures, this 186-page report ?Europe Clinical Trials Market 2022-2031 by Product Category (Drugs, Devices ...

Request To Download Free Sample of This Strategic Report@ Highlighted with 148 tables and 111 figures, this 241-page report ?Global Clinical Trials Market 2022-2031 by Product Category (Drugs, ...

The funding will be used to complete the Phase II/III trial of ulviprubart, and to support commercial launch preparation.

Biogen and Eisai have spent much of Leqembi’s launch convincing physicians and patients that it’s safe to treat Alzheimer’s ...